Policy & Regulation
Organogenesis Names Grow as Chief Commercial Officer, Bilbo as Chief Operating Officer
19 September 2017 - - US-based regenerative medicine company Organogenesis Inc has elevated two longtime company employees, Brian Grow and Patrick Bilbo, to chief commercial officer and...
Aldeyra Therapeutics Prices USD 25m Stock Offering
19 September 2017 - - US-based biotechnology company Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has priced an underwritten public offering of 3.45m shares of its common stock at a public offering price...
Cellular Biomedicine Validates BioLife Solutions CryoStor Cell Freeze Media for Clinical Trial of AlloJoin
19 September 2017 - - US-based clinical-stage biopharmaceutical firm Cellular Biomedicine Group (NASDAQ: CBMG) has validated US-based cell and tissue hypothermic storage and cryopr...
Becton, Dickinson Launches New 6mm Pen Needle for Injection Pens
19 September 2017 - - US-based medical technology company BD (Becton, Dickinson and company) (NYSE: BDX) has launched the BD Ultra-Fine micro pen needle 6mm x 32G for use with leading pen injecti...
FDA Approves Optinose's Xhance Nasal Spray for the Treatment of Nasal Polyps
19 September 2017 - - Yardley, Pennsylvania-based otolaryngology and allergy therapeutics developer Optinose has received approval from the US Food and Drug Administration (FDA) of its New Drug Applic...
Mitobridge Licenses Intellectual Property Related to NAD+ Modulation as a Therapeutic Approach for Improving Mitochondrial Function
19 September 2017 - - Cambridge, Massachusetts-based mitochondrial function-focused Mitobridge, Inc. has broadened its therapeutic approach to include nicotinamide adenine dinucleotide (NAD+) pathway ...